ZGNX News and Press, Zogenix Inc. From 06/27/19

Dova Pharmaceuticals (NASDAQ: DOVA ) +32%  as FDA OKs Dova's Doptelet for low blood platelets in ITP patients. More news on: Dova Pharmaceuticals, Inc., Atossa Genetics Inc., Zogenix, Inc., Stocks on the move, Read more ...

Zogenix (NASDAQ: ZGNX ) is up  22%  premarket on increased volume in response to its announcement that it expects to resubmit its U.S. marketing application next month for FINTEPLA (fenfluramine) for the treatment of seizures associated with a severe type of epilepsy called Drave...

EMERYVILLE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final minutes from the U.S. Food and Drug Administration (FDA) from the Type A meeting held on May...

Introduction Zogenix ( ZGNX ) is developing low-dose fenfluramine, ZX008, for the treatment of pediatric epileptic syndromes (e.g. Dravet and Lennox-Gastaut). My original investment thesis in Zogenix was based upon the following beliefs: The efficacy of ZX008 supports use as standar...

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...

SAN FRANCISCO, June 06, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in ZGNX and APYX of immediately approaching lead plaintiff deadlines in pending securities class actions. Zogenix, Inc. (NASDAQ: ZGNX) CLASS PERIOD: Feb. 6, 2019 - April 8, 2019...

NEW YORK , May 31, 2019 /PRNewswire/ --  WeissLaw LLP , a national class action and shareholders' rights law firm, announces an investigation of Zogenix, Inc. ("Zogenix" or the "Company) (NASDAQ: ZGNX).   The investigation focuses on possible breaches of fiduciary duty ...

Zogenix, Inc. (ZGNX) Q1 2019 Results Earnings Conference Call May 08, 2019, 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Stephen Farr - Chief Executive Officer Michael Smith - Chief Financial Officer Gail Farfel - Chief Development Officer Ashish Sagrolik...

Zogenix (NASDAQ: ZGNX ): Q1 GAAP EPS of -$0.83 beats by $0.03 . Cash and equivalents of $480.7M Press Release More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news,

Type A meeting with U.S. FDA expected by early June to discuss FINTEPLA® Dravet syndrome NDA expected by early June FINTEPLA Dravet syndrome MAA accepted for review by EMA Exclusive distribution agreement for FINTEPLA in Japan signed with Nippon Shinyaku EMERYVILL...